Nephros, Inc. NEPH PHARMA

Q: What is the current share price of Nephros, Inc. (NEPH)?

As of 2026-09-19 21:16 PDT, Nephros, Inc. (NEPH) trades at $4.36 on NasdaqCM. Its 52-week range is $2.78 to $5.79.

Q: What is the market capitalisation of NEPH?

Nephros, Inc. (NEPH) has a market capitalisation of $47.35M on NasdaqCM.

Q: What is the P/E ratio of NEPH?

NEPH trades at a trailing price-to-earnings (P/E) ratio of 27.25. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 3.91.

Q: What is the return on equity (ROE) of NEPH?

NEPH has a return on equity (ROE) of 16.10%. Its return on capital employed (ROCE) is 10.54%.

Q: Is NEPH a good stock to buy?

This page provides a data-driven analysis of Nephros, Inc. (NEPH), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Healthcare · Medical Instruments & Supplies · United States

https://www.nephros.com

Company Profile ↓

$4.36

+5.83% 1Y

Mkt Cap$47.35M

P/E27.25

P/B3.91

52W High$5.79

52W Low$2.78

Book Value$1.10

EPS (TTM)$0.16

Company Overview

Nephros, Inc., a commercial-stage company, develops and sells water filtration solutions for medical and commercial applications in the United States. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in foodservice and hospitality, and other healthcare facilities. The company also manufactures and sells water filters that enhance the taste and odor of water; reduce biofilm and scale build-up; and remove cysts, particulates, and lead from water systems. It markets its products to food service and hospitality sectors including quick-service restaurants, convenience stores, and restaurants. The company was incorporated in 1997 and is headquartered in South Orange, New Jersey.

Why Investors Should Care

Strong Return on Equity

Generates a return on equity of 16.1%, reflecting efficient use of shareholder capital.

Steady Revenue Expansion

Revenue has grown at a 14.2% CAGR over the past five years.

Healthy Margins

Operating margin of 20.2% supports profitability.

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.07.

Recent Developments

Dec 2025 Revenue of $18.79M (+32.7% YoY); net profit $1.19M.
Trailing 12 Months Year-on-year growth — revenue +36.2%, earnings +450.0%.
5-Year Trend Long-term compounding — revenue CAGR 14.2%.

Growth & Price Performance

Compounded Sales Growth

5 Years:	14.17%
1 Year:	36.20%

Compounded Profit Growth

5 Years:	-
1 Year:	450.00%

Stock Price Performance

1 Year:	+5.83%
6 Months:	+8.73%
3 Months:	+28.61%
1 Month:	+3.56%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish

52-Week Range 52% of range

$2.78 $5.79

Trend Signals

Price vs 50-DMAAbove
Price vs 200-DMAAbove
RSI (14)54.25 · Neutral

Price Performance

1M+3.56%

3M+28.61%

6M+8.73%

1Y+5.83%

Valuation vs Sector

P/E of 27.25 is above the sector median of 24.83 — pricier than peers.

Auto-generated from price history and fundamentals; not investment advice.

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Period: Metric:

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

Compounding revenue at 14.2% over 5 years.

CONS

In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Valuation

Stock P/E

27.25

Industry PE

24.83

Forward P/E

20.76

PEG Ratio

Book Value

$1.10

Price to Book

3.91

P/S

2.26

EV/EBITDA

23.89

Dividend Yield

0.00%

Growth (CAGR)

Revenue 5Y

14.17%

Profit 5Y

Revenue (YoY)

36.20%

Earnings (YoY)

450.00%

Profitability & Returns

ROCE

10.54%

ROE

16.10%

ROA

7.33%

Profit Margin

8.38%

Op Margin

20.16%

Gross Margin

61.26%

EPS (Latest Qtr)

$0.11

EPS (TTM)

$0.16

Balance Sheet & Liquidity

Debt/Equity

0.07

Quick Ratio

2.63

Current Ratio

4.07

Debt

$872.00K

Total Assets

$15.77M

Current Assets

$11.50M

Working Capital

$8.46M

Ownership

Promoter Holding

12.89%

Chg in Prom Hold

0.02%

FII / Inst Holding

17.84%

Chg in FII Hold

Financial Snapshot

Enterprise Value

$47.35M

Total Revenue (TTM)

$20.72M

EBITDA

$1.76M

Free Cash Flow

$-1.45M

Operating Cash Flow

$-661.00K

Shares Outstanding

10.86M

Gross Margin

61.26%

Payout Ratio

0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	NEPH Nephros, Inc. PHARMA	4.36	27.25	$47.35M	0.00%	10.54%	16.10%	14.17%	-
2	LLY Eli Lilly and Company SPXR3KPHARMA	1,123.91	37.80	$1.00T	0.60%	-	102.29%	7.20%	11.41%
3	JNJ Johnson & Johnson SPXR3KPHARMA	269.12	31.22	$648.55B	1.98%	14.88%	25.74%	2.43%	4.76%
4	ABBV AbbVie Inc. SPXR3KPHARMA	248.78	70.48	$439.62B	2.78%	10.47%	-129.24%	1.75%	-29.06%
5	MRK Merck & Co., Inc. SPXR3KPHARMA	148.46	118.77	$366.28B	2.31%	-	6.96%	5.64%	10.01%
6	UNH UnitedHealth Group Incorporated SPXR3KPHARMA	400.84	25.74	$359.79B	2.47%	9.74%	14.15%	10.40%	5.43%
7	NVS Novartis AG PHARMA	137.70	20.80	$261.73B	3.36%	21.09%	30.35%	9.25%	26.22%
8	AZN AstraZeneca PLC NDXPHARMA	160.04	23.99	$248.20B	2.00%	15.97%	21.96%	9.82%	45.96%
9	TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA	603.02	32.49	$222.97B	0.29%	8.14%	13.51%	8.81%	12.95%

Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric	Mar 2014	Jun 2014	Sep 2014	Mar 2015	Jun 2015	Sep 2015	Mar 2016	Jun 2016	Sep 2016	Mar 2017	Jun 2017	Sep 2017	Mar 2018	Jun 2018	Sep 2018	Mar 2019	Jun 2019	Sep 2019	Mar 2020	Jun 2020	Sep 2020	Mar 2021	Jun 2021	Sep 2021	Mar 2022	Jun 2022	Sep 2022	Mar 2023	Jun 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue	-	-	-	-	-	-	-	-	-	-	859.00K	916.00K	985.00K	1.37M	1.72M	1.77M	2.31M	3.10M	2.53M	1.58M	2.12M	2.74M	2.27M	2.58M	2.16M	2.85M	2.41M	3.70M	3.54M	3.74M	3.52M	3.25M	3.52M	-	4.88M	4.42M	4.76M	4.73M	5.21M	6.02M
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.72M	1.62M	1.85M	1.97M	2.22M	-
Gross Profit	367.00K	299.00K	316.00K	282.00K	358.00K	166.00K	295.00K	297.00K	316.00K	455.00K	517.00K	532.00K	467.00K	830.00K	952.00K	998.00K	1.37M	1.82M	1.49M	895.00K	1.23M	1.59M	1.27M	1.36M	1.05M	1.40M	762.00K	2.11M	2.08M	2.19M	2.19M	1.91M	2.15M	-	3.15M	2.79M	2.92M	2.76M	2.99M	4.03M
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2.59M	2.55M	2.60M	2.74M	2.90M	-
Operating Income	-562.00K	-636.00K	-681.00K	-806.00K	-594.00K	-1.09M	-806.00K	-817.00K	-637.00K	-605.00K	-700.00K	-518.00K	-1.12M	-653.00K	-511.00K	-1.30M	-868.00K	-695.00K	-1.03M	-1.60M	-932.00K	-1.02M	-1.12M	-802.00K	-1.55M	-814.00K	-1.28M	-306.00K	-435.00K	-203.00K	-200.00K	-317.00K	206.00K	-	566.00K	248.00K	314.00K	18.00K	97.00K	1.21M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	606.00K	282.00K	374.00K	94.00K	126.00K	-
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	1.00K	0	0	-	-
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	558.00K	246.00K	340.00K	62.00K	140.00K	-
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	9.00K	3.00K	0	-	-
Net Income	-3.51M	-5.34M	2.72M	243.00K	-1.81M	-581.00K	-836.00K	-835.00K	-706.00K	-680.00K	-786.00K	-632.00K	-1.43M	-682.00K	-566.00K	-1.35M	-942.00K	-744.00K	-1.10M	-1.66M	-1.01M	-537.00K	-1.13M	-1.22M	-1.97M	-1.14M	-3.23M	-306.00K	-433.00K	-182.00K	-169.00K	-289.00K	183.00K	-	558.00K	237.00K	337.00K	62.00K	140.00K	1.20M
Diluted EPS	-0.19	-	-0.02	-0.02	-	-0.02	-0.02	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-0.12	-0.31	-0.03	-0.04	-0.02	-0.02	-0.03	0.02	0.03	0.05	0.02	0.03	-	0.01	0.11
R&D Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	352.00K	756.00K	793.00K	777.00K	563.00K	836.00K	751.00K	556.00K	487.00K	395.00K	372.00K	273.00K	252.00K	239.00K	221.00K	205.00K	212.00K	254.00K	188.00K	-	295.00K	311.00K	338.00K	-	346.00K	366.00K

Profit & Loss (Annual)

Figures in USD.

Metric	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	-	2.94M	2.21M	1.81M	1.74M	1.75M	1.94M	2.32M	3.81M	5.69M	10.33M	8.56M	-	9.97M	14.24M	14.16M	18.79M
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	5.24M	5.83M	5.44M	7.16M
Gross Profit	-	1.12M	868.00K	1.07M	842.00K	1.20M	1.06M	1.29M	2.29M	3.20M	6.08M	4.91M	-	4.73M	8.40M	8.72M	11.62M
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	9.07M	10.00M	8.72M	10.48M
Operating Income	-	-1.89M	-2.31M	-3.33M	-3.32M	-2.67M	-3.42M	-2.87M	-2.23M	-3.02M	-3.15M	-4.28M	-	-4.33M	-1.59M	6.00K	1.15M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-3.91M	-1.36M	227.00K	1.35M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	20.00K	2.00K	1.00K	1.00K
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-4.28M	-1.57M	89.00K	1.21M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	15.00K	12.00K
Net Income	-12.08M	3.88M	-7.00M	-6.62M	1.32M	-7.37M	-3.09M	-3.03M	-809.00K	-3.40M	-3.18M	-4.53M	-	-7.38M	-1.57M	74.00K	1.19M
Diluted EPS	-	1.86	-	-	-0.18	-0.31	-	-	-	-	-	-	-	-0.70	-0.15	0.01	0.11
R&D Expense	-	-	-	-	-	-	-	-	-	1.54M	3.09M	2.76M	1.50M	1.25M	873.00K	906.00K	1.34M

Balance Sheet (Annual)

Figures in USD.

Metric	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Assets	-	1.59M	3.99M	3.53M	2.89M	3.37M	3.97M	2.68M	4.98M	10.56M	11.63M	18.51M	-	11.00M	11.86M	11.21M	13.64M
Current Assets	-	-	-	-	-	-	-	-	-	-	-	-	-	8.26M	8.40M	8.30M	11.22M
Cash & Equivalents	-	-	-	-	-	-	-	-	-	-	4.17M	8.25M	-	3.63M	4.31M	3.76M	5.40M
Inventory	-	-	-	-	-	-	-	-	-	-	-	-	-	3.15M	2.47M	2.62M	3.23M
Receivables	-	-	-	-	-	-	-	-	-	-	-	-	-	1.29M	1.50M	1.78M	2.41M
Total Liabilities	-	-	2.57M	4.12M	6.61M	9.05M	1.31M	2.01M	3.03M	3.76M	3.94M	2.94M	-	2.12M	3.50M	2.62M	3.44M
Current Liabilities	-	1.46M	1.18M	3.42M	3.50M	1.25M	959.00K	895.00K	1.87M	2.65M	2.43M	1.32M	-	1.41M	2.11M	1.56M	2.77M
Long Term Debt	-	-	-	-	-	-	-	-	-	1.04M	824.00K	593.00K	99.00K	1.00K	-	-	-
Total Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	1.09M	1.84M	1.41M	1.06M
Total Equity	1.96M	135.00K	1.42M	-595.00K	-3.72M	-5.68M	-2.66M	667.00K	1.95M	3.80M	4.67M	12.52M	-	5.59M	8.36M	8.59M	10.20M
Shares Outstanding	-	-	-	-	-	-	-	-	-	-	-	-	-	10.30M	10.54M	10.54M	10.64M

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2010	Dec 2012	Dec 2013	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	-	-	-	-	-	-77.00K	-3.66M	-2.28M	-6.90M	-	-3.23M	827.00K	-492.00K	1.65M
Investing Cash Flow	-	-	-	-	-	-	-991.00K	-151.00K	-239.00K	-	-137.00K	-75.00K	-50.00K	0
Financing Cash Flow	-	-	-	-	-	1.99M	7.05M	2.02M	11.22M	-	34.00K	-79.00K	-5.00K	-5.00K
Capital Expenditure	-30.00K	-8.00K	-0	-13.00K	-45.00K	-	-	-14.00K	-239.00K	-36.00K	-137.00K	-75.00K	-55.00K	-
Free Cash Flow	-	-	-	-	-	-	-	-2.29M	-7.14M	-	-3.37M	752.00K	-547.00K	1.65M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-	-3.34M	673.00K	-547.00K	1.64M

Ratios (Annual)

Figures in %.

Metric	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	-	38.2%	39.2%	59.2%	48.4%	68.6%	54.5%	55.8%	60.2%	56.3%	58.9%	57.4%	-	47.4%	59.0%	61.6%	61.9%
Operating Margin %	-	-64.3%	-104.3%	-184.4%	-190.6%	-152.7%	-176.0%	-123.7%	-58.4%	-53.0%	-30.5%	-49.9%	-	-43.5%	-11.2%	0.0%	6.1%
Net Margin %	-	132.1%	-316.1%	-366.5%	76.0%	-421.7%	-158.8%	-130.7%	-21.2%	-59.8%	-30.8%	-52.9%	-	-74.0%	-11.1%	0.5%	6.4%
ROE %	-617.1%	2,874.1%	-492.5%	1,113.1%	-35.5%	129.7%	115.9%	-454.6%	-41.5%	-89.6%	-68.0%	-36.1%	-	-132.0%	-18.8%	0.9%	11.7%
ROCE %	-	-1,399.3%	-82.0%	-2,975.9%	543.8%	-125.8%	-113.6%	-160.9%	-71.5%	-38.2%	-34.3%	-24.9%	-	-45.2%	-16.3%	0.1%	10.5%

Shareholding Pattern

Insiders

12.89%

Institutions

17.84%

Public Float

20.48%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Wexford Capital LP	46.93%	3.60M	$15.52M
2	Topline Capital Management, LLC	6.98%	535.70K	$2.31M
3	Vanguard Capital Management LLC	2.59%	198.64K	$856.15K
4	Cornerstone Capital, Inc.	1.68%	128.70K	$554.70K
5	Morgan Stanley	1.68%	128.91K	$555.62K
6	Bard Associates Inc.	1.54%	118.00K	$508.59K
7	Renaissance Technologies, LLC	1.01%	77.50K	$334.04K
8	Geode Capital Management, LLC	0.92%	70.26K	$302.83K
9	Mesirow Financial Investment Management, Inc.	0.78%	60.00K	$258.60K
10	HighTower Advisors, LLC	0.78%	59.71K	$257.35K

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for NEPH

Google News Fri, 04 Sep 2026

Nephros Stock Price Forecast. Should You Buy NEPH? - StockInvest.us

<a href="https://news.google.com/rss/articles/CBMiSEFVX3lxTFAySThsWGMxdWdrRkRXMjdDWkhjVVRuSTkxdmRnNHZjTVlxQ25oNFFFcjZqTlFrSnloRlk3OUx2dlFBRmg3Q29VVg?oc=5" target="_blank">Nephros Stock Price Forecast. Should You Buy NEPH?</a>  <fo…

Google News hu, 20 Aug 2026

Wexford Capital adds Nephros (NEPH) shares in cashless option move - Stock Titan

<a href="https://news.google.com/rss/articles/CBMiqAFBVV95cUxQdUNUX2VueTRlVC1SVFNIWDBieDZZU0hzVUlSem1uaWRWRE1CWGdzeU42SHNRYjJUMnIxZWRQUm5EVWl4c1RYZzNNUF9KMzY2bndISFVGdXdFaUl1U1NjcF9rYXJ4UEkwUUVESGZVWjN0SUc2enlUUzc4cEh4SmdLUU9HNEpUc1JZaWVEVE…

Google News hu, 28 May 2026

NEPH - Finviz

<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE9qQlpwYUtqNkRjQUpja0MtZVdpWG5EXzZwU3FWa2JkVkx2QTVPRFpadW1zMl9DbWphdXVzZW9XVEdmUURjeEE?oc=5" target="_blank">NEPH</a>  <font color="#6f6f6f">Finviz</font>…

Google News Fri, 06 Feb 2026

Nephros, Inc.'s (NASDAQ:NEPH) Popularity With Investors Under Threat As Stock Sinks 28% - simplywall.st

<a href="https://news.google.com/rss/articles/CBMiywFBVV95cUxNZ1FmUE5OdHlnMF95OWdlVnJldk5TTExRTmtsamI0TWM0b1hvaHVpTElNZE5mbndjR3NfSGtxZkFEZWt1NXJaeVVFbFZTTXNCMUp0N0F4NjRUUlROd3hvNmhyZWNjNXJvMmVWQzRkM3ZzUUx4RHZzU1EtQUNNNGlhOXExb3FMTjhQWDNIOT…

Google News Fri, 13 Feb 2026

Nephros, Inc. Expands into Puerto Rican Market to Address Water Filtration Needs in Healthcare and Hospitality Sectors - Quiver Quantitative

<a href="https://news.google.com/rss/articles/CBMi6AFBVV95cUxQYkNjNEpsYWdoX1dmNm5xU29wdWVxX2lzOEp5ZEZXTUFyUnBxOHo3dWd4LU42LVpjU1lYX1dYWWdTbFlTMGJmNk5BYU1jcWszeHFIeE40NEFINmQ0ZWlRQXBIMXpzVUtjN2pZcGVhSG1yUUJXOUxmVl9uVVJWeUtvTldxRW1TU05mam9Qd3…

Google News Fri, 21 Nov 2025

3 Intriguing Penny Stocks With Market Caps At Least $50M - finance.yahoo.com

<a href="https://news.google.com/rss/articles/CBMihAFBVV95cUxQZXMxa0ZiUzY5UVVCd0FKSGFZcmVGaTVTRFhXVElEMGdHNzFNbEc2T2xKSVdJRFhMcXNzTXRlX05XVmwwdTZ2c2dMalM4U2Jsd1BYcDV1YWo3YVQ5WXNxaHh1OHZkT1gzcUU2WjhqWU5KTzBNVWswbnpoUjdFQVptbVUweDg?oc=5" targ…

NEPH — Frequently Asked Questions

What is the current share price of Nephros, Inc. (NEPH)?

As of 2026-09-19 21:16 PDT, Nephros, Inc. (NEPH) trades at $4.36 on NasdaqCM. Its 52-week range is $2.78 to $5.79.

What is the market capitalisation of NEPH?

Nephros, Inc. (NEPH) has a market capitalisation of $47.35M on NasdaqCM.

What is the P/E ratio of NEPH?

NEPH trades at a trailing price-to-earnings (P/E) ratio of 27.25. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 3.91.

What is the return on equity (ROE) of NEPH?

NEPH has a return on equity (ROE) of 16.10%. Its return on capital employed (ROCE) is 10.54%.

Is NEPH a good stock to buy?

This page provides a data-driven analysis of Nephros, Inc. (NEPH), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks

Nephros, Inc. NEPH PHARMA

Company Overview

Why Investors Should Care

Recent Developments

Growth & Price Performance

Compounded Sales Growth

Compounded Profit Growth

Stock Price Performance

Price Chart

Technical Trend

Fundamental Growth Charts

PROS

CONS

Valuation

Growth (CAGR)

Profitability & Returns

Balance Sheet & Liquidity

Ownership

Financial Snapshot

Peer comparison

Quarterly Results

Profit & Loss (Annual)

Balance Sheet (Annual)

Cash Flows (Annual)

Ratios (Annual)

Shareholding Pattern

Top Institutional Holders

Analyst View

Latest News

Nephros Stock Price Forecast. Should You Buy NEPH? - StockInvest.us

Wexford Capital adds Nephros (NEPH) shares in cashless option move - Stock Titan

NEPH - Finviz

Nephros, Inc.'s (NASDAQ:NEPH) Popularity With Investors Under Threat As Stock Sinks 28% - simplywall.st

Nephros, Inc. Expands into Puerto Rican Market to Address Water Filtration Needs in Healthcare and Hospitality Sectors - Quiver Quantitative

3 Intriguing Penny Stocks With Market Caps At Least $50M - finance.yahoo.com

NEPH — Frequently Asked Questions

What is the current share price of Nephros, Inc. (NEPH)?

What is the market capitalisation of NEPH?

What is the P/E ratio of NEPH?

What is the return on equity (ROE) of NEPH?

Is NEPH a good stock to buy?

Explore More